Macrophage polarization (Interferon-gamma and Interleukin-4 pathways) (M1/M2 polarization)

Macrophage polarization is the biological process by which macrophages adopt distinct functional phenotypes—classically activated (M1) or alternatively activated (M2)—in response to environmental stimuli (Murray, 2017, Immunity). The M1 phenotype is primarily driven by Interferon-gamma (IFN-gamma) signaling through the IFN-gamma receptor (IFNGR) and the JAK1/2-STAT1 pathway, leading to the production of pro-inflammatory cytokines and reactive oxygen species (Hu and Ivashkiv, 2009, Nature Immunology). Conversely, the M2 phenotype is induced by Interleukin-4 (IL-4) or IL-13 signaling through the IL-4 receptor alpha (IL-4Ra) and the JAK1/3-STAT6 pathway, which promotes tissue repair and anti-inflammatory responses (Ginhoux et al., 2016, Nature Immunology). In clinical contexts, dysregulated polarization is linked to diseases such as cancer, where tumor-associated macrophages (TAMs) often exhibit an M2-like profile that suppresses anti-tumor immunity (Mantovani et al., 2017, Nature Reviews Clinical Oncology). Therapeutic strategies target these pathways using agents like Dupilumab to block IL-4Ra in allergic diseases or JAK inhibitors like Tofacitinib to dampen M1-mediated inflammation (Woytschak and Boyman, 2014, Modern Rheumatology). Monitoring polarization involves biomarkers such as CD80/CD86 for M1 and CD206/Arg1 for M2 states (Yunna et al., 2020, Frontiers in Cell and Developmental Biology). These pathways represent critical nodes for immunomodulatory drug development across oncology and inflammatory therapeutic areas.

Other names

Classical and alternative macrophage activationM1/M2 macrophage polarizationIFN-gamma/IL-4 signaling axis

Modulation of macrophage functional states by activating or inhibiting cytokine-mediated JAK-STAT signaling pathways to shift the balance between pro-inflammatory and anti-inflammatory phenotypes.